VTVT News and Press, vTv Therapeutics Inc. From 06/04/23

2023-06-04 12:00:08 ET Billions of dollars in sales across various MedTech markets will be at stake if there is a broader acceptance of weight loss drugs developed by Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), Morgan Stanley argued in a research note last week. Novo N...

2023-05-24 09:24:44 ET vTv Therapeutics ( NASDAQ: VTVT ) added ~13% in the pre-market Wednesday after announcing that its partner Cantex Pharmaceuticals received a U.S. patent that covers claims related to experimental brain tumor therapy azeliragon. In June 2021, Cantex rea...

HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that the United States Patent and Tradem...

2023-05-11 17:15:05 ET vTv Therapeutics press release ( NASDAQ: VTVT ): Q1 GAAP EPS of -$0.06 beats by $0.05 . The Company’s cash position as of March 31, 2023, was $18.8 million compared to $12.1 million as of December 31, 2022. The increase is attrib...

HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter e...

2023-05-07 12:00:27 ET Patients in the U.S are expected to dish out $10B on obesity medicines in 2027, marking an $8.1B rise or over 378% growth for the period 2023 – 2027, the latest industry report on pharma spending from the drug analytics firm IQVIA Holdings ( IQV ) indicates...

2023-04-27 06:55:09 ET Eli Lilly ( NYSE: LLY ) announced Thursday that its experimental weight loss therapy, tirzepatide, generated up to 15.7% of weight loss, and the company expects the FDA to decide on its approval as early as late 2023. Tirzepatide, a glucose-dependent insul...

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 PR Newswire WESTON, Fla. and ANN ARBOR, M...

2023-03-17 13:01:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to finding good p harma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ul...

2023-03-12 13:00:16 ET New weight loss therapies could cause a significant strain on Medicare due to cost implications, a group of health experts warned last week in an article published in The New England Journal of Medicine on Saturday amid legislative efforts to gain coverage. ...